211 related articles for article (PubMed ID: 32493618)
1. Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.
Coleman CI; Thompson S; Ashton V; Palladino M; Bunz TJ
J Natl Med Assoc; 2020 Aug; 112(4):395-401. PubMed ID: 32493618
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
Curr Med Res Opin; 2020 Jul; 36(7):1081-1088. PubMed ID: 32347755
[No Abstract] [Full Text] [Related]
3. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
4. Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Baker WL; Sood NA; Bunz TJ; Meinecke AK; Eriksson D; Coleman CI
Pharmacotherapy; 2019 Feb; 39(2):196-203. PubMed ID: 30597611
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin.
Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N
Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation.
Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Alonso A
J Cardiol; 2017 Jun; 69(6):868-876. PubMed ID: 27889397
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban Versus Warfarin for Management of Obese African Americans With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective Cohort Analysis.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
Clin Appl Thromb Hemost; 2020; 26():1076029620954910. PubMed ID: 33085526
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
Martinez BK; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
[TBL] [Abstract][Full Text] [Related]
10. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
12. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
[TBL] [Abstract][Full Text] [Related]
13. Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding.
Lip GYH; Keshishian AV; Zhang Y; Kang A; Dhamane AD; Luo X; Klem C; Ferri M; Jiang J; Yuce H; Deitelzweig S
JAMA Netw Open; 2021 Aug; 4(8):e2120064. PubMed ID: 34398204
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation.
Norby FL; Bengtson LGS; Lutsey PL; Chen LY; MacLehose RF; Chamberlain AM; Rapson I; Alonso A
BMC Cardiovasc Disord; 2017 Sep; 17(1):238. PubMed ID: 28874129
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes.
Baker WL; Beyer-Westendorf J; Bunz TJ; Eriksson D; Meinecke AK; Sood NA; Coleman CI
Diabetes Obes Metab; 2019 Sep; 21(9):2107-2114. PubMed ID: 31099460
[TBL] [Abstract][Full Text] [Related]
16. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
17. Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study.
Fu EL; Desai RJ; Paik JM; Kim DH; Zhang Y; Mastrorilli JM; Cervone A; Lin KJ
Am J Kidney Dis; 2024 Mar; 83(3):293-305.e1. PubMed ID: 37839687
[TBL] [Abstract][Full Text] [Related]
18. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
Milentijevic D; Lin JH; Connolly N; Chen YW; Kogan E; Shrivastava S; Sjoeland E; Alberts MJ
J Stroke Cerebrovasc Dis; 2021 May; 30(5):105715. PubMed ID: 33743312
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients With Valvular Atrial Fibrillation : A Population-Based Cohort Study.
Dawwas GK; Dietrich E; Cuker A; Barnes GD; Leonard CE; Lewis JD
Ann Intern Med; 2021 Jul; 174(7):910-919. PubMed ID: 33780291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]